Pulmonary Pharmacology & Therapeutics, 2010 Bronchodilators are the cornerstone of pharmacological management of COPD. For patients whose conditions are not sufficiently controlled by monotherapy, combining bronchodilators of different classes, in particular an inhaled muscarinic antagonist with ...
CAZZOLA, MARIO, Molimard, M.
core +5 more sources
Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study. [PDF]
Clin Pharmacol Drug Dev, 2020 Borin MT +5 more
europepmc +2 more sources
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Expert Opinion on Investigational Drugs, 2010 : Importance of the field. The prevention and relief of symptoms by regular use of bronchodilators is central to the pharmacological management of chronic obstructive pulmonary disease (COPD).
Joos, Guy
core +3 more sources
Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. [PDF]
Int J Chron Obstruct Pulmon Dis, 2018 A large body of evidence suggests that long-acting β2-adrenoceptor agonist (LABA)/long-acting muscarinic antagonist (LAMA) combinations induce a strong synergistic bronchodilatory effect in human isolated airways. Moreover, a recent post hoc analysis demonstrated clinical synergism between LABAs and LAMAs, which induces a synergistic improvement not ...
Yamada H, Hida N, Hizawa N.
europepmc +6 more sources
Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium. [PDF]
Biomed Res Int, 2018 Severe asthma is associated with substantial morbidity and mortality. Therapies must be maximized to gain control of a patient’s severe asthma; however, avoiding overtreatment is also important. The mainstays of asthma maintenance treatment are inhaled corticosteroids (ICS) and long-acting β2-agonsits (LABAs), with the option of supplementary add-on ...
Hamelmann E.
europepmc +4 more sources
Long‐acting muscarinic antagonists and small airways in asthma: Which link? [PDF]
Allergy, 2021 AbstractInvolvement of small airways, those of <2 mm in internal diameter, is present in all stages of asthma and contributes substantially to its pathophysiologic expression. Therefore, small airways are a potential target to achieve optimal asthma control.
Mario Cazzola +2 more
openaire +3 more sources
Understanding the role of long-acting muscarinic antagonists in asthma treatment
Annals of Allergy, Asthma & Immunology, 2022 Long-acting muscarinic antagonists (LAMAs) have been used in the treatment of obstructive pulmonary diseases for years. Long-acting muscarinic antagonists were previously mainly used as bronchodilators in chronic obstructive pulmonary disease, but the use of LAMAs in the treatment of asthma has gained great interest.
Susan, Muiser +3 more
openaire +4 more sources
Single inhaler triple therapy in COPD – all that glitters is not gold
Monaldi Archives for Chest Disease, 2021 Dear Editor, The recent studies on combination triple therapy of inhaled corticosteroid, long acting beta2 agonist and long-acting muscarinic antagonist (ICS-LABA-LAMA) in COPD have consistently demonstrated an improvement in exacerbation frequency and/
Kartik Deshmukh, Arjun Khanna
doaj +1 more source
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium [PDF]
BMC Pulmonary Medicine, 2021 AbstractBackgroundMucociliary clearance (MCC) is an essential defense mechanism in airway epithelia for removing pathogens from the respiratory tract. Impaired ciliary functions and MCC have been demonstrated in asthma and chronic obstructive pulmonary disease (COPD).
Mineo Katsumata +17 more
openaire +3 more sources
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma [PDF]
Allergy, Asthma & Immunology Research, 2017 Despite a range of efficacious therapies for asthma, including inhaled corticosteroids (ICS) and long-acting β₂-agonists (LABA), a significant proportion of patients have poor asthma control and retain a risk of future worsening of their symptoms. Long-acting muscarinic antagonist (LAMA) bronchodilators offer a well-tolerated, efficacious, and cost ...
René Aalbers, Hae-Sim Park
openaire +2 more sources